招銀国际
CMB INTERNATIONAL

CMBI Research Focus List

Our best high conviction ideas

6 Sep 2021

CMBI Focus List – Long and short ideas

Company	Ticker	Sector	Rating	M cap (US$ bn)	3M ADTV (US$ mn)	Price (LC)	TP (LC)	Up/Down -side	P/E (x) FY21E	P/E (x) FY22E	P/B (x) FY21E	ROE FY21E	Yield FY21E	Analyst
Long Ideas														
BYD – H	1211 HK	Auto	BUY	109.8	363.8	260.8	405.0	55%	84.6	54.1	8.8	11.3	0.1%	Jack Bai/ Robin Xiao
Zhejiang Dingli	603338 CH	Capital Goods	BUY	5.5	72.9	73.1	87.0	19%	37.8	28.5	7.9	23.0	0.5%	Wayne Fung
SANY International	631 HK	Capital Goods	BUY	4.1	6.9	10.2	14.3	40%	20.4	16.9	3.1	16.1	2.2%	Wayne Fung
ZTO Express	2057 HK	Express Delivery	BUY	25.8	2.6	242.2	306.0	26%	33.3	25.2	3.0	9.3	0.9%	Wayne Fung
Li Ning	2331 HK	Consumer Disc.	BUY	32.4	204.9	100.8	102.8	2%	60.1	49.1	17.6	30.0	0.5%	Walter Woo
Prada	1913 HK	Consumer Disc.	BUY	15.2	7.8	46.1	68.1	48%	53.1	38.8	4.4	8.6	1.1%	Walter Woo
Innovent Biologics	1801 HK	Healthcare	BUY	12.5	66.2	66.5	116.9	76%	NA	NA	NA	-20.0	0.0%	Jill Wu/ Sam Hu/ Jonathan Zhao
China Pacific Insurance	2601 HK	Insurance	BUY	39.1	36.7	24.6	36.0	46%	NA	NA	0.8	12.4	7.4%	Gigi Chen
Meituan	3690 HK	Internet	BUY	188.5	993.4	239.0	383.0	60%	NA	NA	NA	-31.1	0.0%	Sophie Huang/ Miriam Lu
Bilibili	BILI US	Internet	BUY	33.0	486.3	86.0	110.0	28%	NA	NA	NA	-22.6	0.0%	Sophie Huang/ Miriam Lu
CR Land	1109 HK	Property	BUY	27.2	56.8	29.7	44.8	51%	4.8	4.4	1.1	14.6	4.6%	Jeffrey Zeng
CG Services	6098 HK	Property	BUY	26.0	102.9	62.6	91.2	46%	30.0	21.4	32.9	25.8	0.7%	Jeffrey Zeng
China Hongqiao	1378 HK	Materials	BUY	11.9	31.7	10.2	15.0	48%	4.4	4.2	0.7	22.2	10.7%	Robin Xiao
BYDE	285 HK	Technology	BUY	10.2	43.2	35.2	49.5	41%	16.9	11.8	3.8	15.5	0.6%	Alex Ng/ Lily Yang
Willsemi	603501 CH	Technology	BUY	32.2	421.7	239.2	370.8	55%	46.0	34.3	13.4	28.5	0.0%	Lily Yang/ Alex Ng
Hikvision	002415 CH	Software & IT services	BUY	74.6	366.4	51.6	80.0	55%	28.2	23.1	7.5	29.0	0.0%	Marley Ngan

Source: Bloomberg, CMBIS, Price as of 6/9/2021 (11am)

招銀国际 CMB INTERNATIONAL

Latest additions/deletions from CMBI Focus List

Company	Ticker	Sector	Rating	Analyst	Rationale
Additions					
Zhejiang Dingli	603338 CH	Capital Goods	BUY	Wayne Fung	We upgraded the stock to BUY in late Aug and expect a continuous rebound in the near term. Key reasons: (1) ambitious AWP fleet size expansion by Far East Horizon (3360 HK) should help boost Dingli's AWP volume growth; (2) significant upside of steel and freight cost seems to be less likely, which should help stabilize the gross margin.
ZTO Express	2057 HK	Express Delivery	BUY	Wayne Fung	We believe the government's strong intervention in the express delivery industry will help stop the prolonged cut-throat price war. We start to see some express delivery operators shifting the strategy focus from volume to profitability.
Willsemi	603501 CH	Technology	BUY	Lily Yang/ Alex Ng	Strong growth in the future driven by CIS business. We view recent correction as an attractive opportunity for investors to gain exposure to quality Chinese semi fabless names that can ride strategic trends.
Deletions					
Zhejiang Jingsheng	300316 CH	Capital Goods	BUY	Wayne Fung	We remain positive on the robust solar capex growth story over the coming two years. However, from a short-term perspective, we believe the stock, after the strong run over the past couple of months, has priced-in the near term positives, in particular the mega contract signed with Zhonghuan (002129 CH).
WH	288 HK	Consumer Staples	BUY	Albert Yip	We remove the stock as we see a lack of catalyst in the near term.
Hope Education	1765 HK	Education	BUY	Albert Yip	We remove the stock as we see a lack of catalyst in the near term.
ZTE	763 HK	Technology	BUY	Lily Yang/ Alex Ng	Although we hold a positive view on ZTE, the uncertainty in telco's future 5G deployment in China remains a key concern for the market.

Source: CMBIS

Performance of our recommendations

- In our last report dated 9 Aug, we highlighted a list of 17 long ideas.
- The performance of the basket (equal weighted) with these 17 stocks outperformed MSCI China index by 0.8ppt, delivering 1.7% return (vs MSCI China 0.9%).
- Li Ning, CR Land and Zhejiang Jingsheng delivered 15% or above return, and 10 of our 17 long ideas outperformed the benchmark.



Source: Bloomberg, CMBIS; Note: Stock performance from 6 Aug 2021 to 3 Sep 2021

Long Ideas

BYD – H (1211 HK): Long-term trend remains intact

Rating: BUY **| TP:** HK$405 (55% upside)

Analysts: Jack Bai/ Robin Xiao

- **Investment Thesis:** BYD's Apr auto sales volume was 45,234 units, exhibiting a strong rebound MoM by 40.4%. NEV sales volume accounted for 56.7%, and we think PHEV sales was a highlight in Apr. On the back of strong DM-I series PHEV orders and production ramp up pace, we still expect BYD's performance to improve MoM from Apr and the trend will continue in the remaining months in 2021E. We maintain BYD as our top pick for NEV sector, and our TP remains unchanged at HK$405.

- **Auto sales to pick up from Apr.** DM-i series to become hit product. DM-i series equip with 1.5L Xiaoyun engine, with 43.4% thermal efficiency and running with less than 3.8L fuel consumption per 100km. Whole DM-i series are equipped with dedicated high power blade battery, and have same price as ICE vehicles with extraordinary using experience as EV. We think the high cost performance of DM-I will drive strong retail demand growth. Mgmt. disclosed Qin Plus DM-i has accumulated orders of more than 50K units. We expect cumulative orders to be delivered gradually in 2Q-4Q21E as the dedicated blade battery release capacity output.

- **Suggest to buy on dips.** We think recent share price retreat offer good opportunities to accumulate the stock, as we expect market sentiment will be boosted on 1) auto sales volume boom as DM-I capacity release, and 2) BYD to launch more cooperation for external power battery supply. BYD's current valuation is significantly lower than peers (3x P/S on NEV sales vs. NEV new forces 6x – 12x P/S). We expect BYD's valuation will re-rate with increasing NEV sales proportion and earnings release.

- **Future catalyst:** 1) NEV sales growth to accelerate; 2) power battery to realize external shipment; 3) Semiconductor business to have new update.

- **Link to latest report:** BYD - H (1211 HK) – 业绩扰动短期股价，长期向好趋势未改

Financials and Valuations

(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E
Revenue (RMB mn)	156,598	224,413	292,785	356,006
YoY growth (%)	22.59%	43.31%	30.47%	21.59%
Net income (RMB mn)	4,234	4,871	7,494	11,616
EPS (RMB)	1.47	1.64	2.56	4.00
YoY growth (%)	196%	12%	56%	56%
Consensus EPS (RMB)	0.97	1.12	1.47	2.47
P/E (x)	147.10	131.70	84.56	54.12
P/B (x)	10.90	9.96	8.78	7.41
Yield (%)	0.07%	0.08%	0.12%	0.19%
ROE (%)	7.45%	8.18%	11.28%	15.06%
Net gearing (%)	39.7	43.9	46.5	48.3

Source: Company data, Bloomberg, CMBIS estimates

Fig: Valuation by business segment



Source: Company data, CMBIS estimates

Zhejiang Dingli (603338 CH): Margin concerns priced-in; Focus on volume growth

Rating: BUY | **TP:** RMB87.0 (19% upside)

Analyst: Wayne Fung

- **Investment Thesis:** Aerial working platform (AWP) is entering a structural growth trajectory as the rising labor cost in China will make AWPs incrementally cost competitive compared with the traditional scaffolding. We believe Zhejiang Dingli, as a pure AWP manufacturer, remains a major beneficiary given its global presence, cost competitiveness, brand recognition and strong management execution.

- **Our View.** We upgraded Dingli to **BUY** from Hold in late Aug. While Dingli's net profit in 2Q21 grew only 17% YoY as gross margin contraction offset the strong revenue growth of 59%, we believe the results provide investors with an indication of the margin level amid the high steel cost and freight rate.

- **Why do we differ vs consensus:** Our earnings forecast in 2021E/22E is 0%/+1% versus consensus.

- **Catalysts:** We see positives drivers going forward: (1) ambitious AWP fleet size expansion by **Far East Horizon (3360 HK, BUY)**, the major customer of Dingli, should help boost Dingli's AWP volume growth over the coming years; (2) significant upside of steel and freight cost seems to be less likely, which should help stabilize the gross margin.

- **Valuation:** We set our TP at RMB87, based on 44x 2021E target P/E (on the back of ~44% earnings growth in 2021E).

Link to latest report:

Zhejiang Dingli (603338 CH) – Satisfactory results in 2Q; Negatives priced in; U/G to BUY

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	2,957	4,721	5,908	6,868
YoY growth (%)	23.7	59.7	25.2	16.2
Net income (RMB mn)	664	958	1,270	1,497
EPS (RMB)	1.37	1.97	2.62	3.08
YoY growth (%)	-4.3	44.3	32.5	17.9
Consensus EPS (RMB)	N/A	1.98	2.58	3.19
EV/EBIDTA (x)	44.0	33.5	24.5	21.0
P/E (x)	54.5	37.8	28.5	24.2
P/B (x)	9.7	7.9	6.4	5.2
Yield (%)	0.3	0.5	0.7	0.8
ROE (%)	19.1	23.0	24.8	23.8
Net gearing (%)	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: Dingli's revenue breakdown



Source: Company data, CMBIS estimates

SANY International (631 HK): Intelligent products and robotic business to drive sustainable growth

Rating: BUY **| TP:** HK$14.3 (40% upside)

Analyst: Wayne Fung

- **Investment Thesis:** The ongoing development of intelligent coal mines and ports will continue to offer opportunity for SANYI to gain market share through the launch of the intelligent machinery products. Besides, industrial robot and smart mining will serve as new growth drivers for SANYI. On the other hand, the commencement of lighthouse factories in Sep/Oct will enhance SANYI's competitive edge.

- **Our View:** We continue to believe SANYI's transformation strategy is the key to maintain a sustainable growth trajectory over the coming years. For robotic business, we forecast SANYI to deliver segment revenue of RMB1.08bn/RMB1.3bn in 2021E/22E (>10% of total revenue). On the other hand, we believe potential M&A this year will enlarge the scale of the Company in a short period of time.

- **Why do we differ vs consensus:** Our earnings forecast in 2021E/22E is 3/-3% versus consensus estimates. There is only a limited number of analysts covering the stock.

- **Catalysts:** (1) Launch of new products; (2) Strong mining capex; (3) potential M&A.

- **Valuation:** We rolled over our valuation base to 2022E and lifted our TP to HK$14.3 (based on 23x P/E, on the back of 23% earnings CAGR in 2021E-23E) in early Sep. We believe potential M&A will offer additional upside.

Link to latest report:

SANY International (631 HK) – Sustainable growth driven by intelligent mining products and robotic business

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	7,364	10,171	12,562	15,089
YoY growth (%)	30.2	38.1	23.5	20.1
Net income (RMB mn)	1,045	1,341	1,623	1,960
EPS (RMB)	0.34	0.43	0.52	0.63
YoY growth (%)	12.5	27.7	21.0	20.8
Consensus EPS (RMB)	-	0.42	0.53	0.66
EV/EBITDA (x)	17.3	13.9	11.6	9.8
P/E (x)	27.2	20.4	16.9	14.0
P/B (x)	3.6	3.1	2.8	2.5
Yield (%)	1.4	2.2	2.7	3.2
ROE (%)	14.0	16.1	17.5	18.8
Net gearing (%)	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: SANYI's revenue breakdown



Source: Company data, CMBIS estimates

ZTO Express (2057 HK): Cut-throat price war likely come to an end

Rating: BUY | TP: HK$306 (26% upside)

Analyst: Wayne Fung

- **Investment Thesis:** A consultation paper released by the State Administration for Market Regulation in early Jul stated that dumping products at low prices to exclude competitors will be subject to five times the unlawful earnings. On the other hand, in late Aug, the major express delivery operators, namely ZTO, YTO, STO, BEST, Yunda and J&T Express, decided to revise up the dispatch fee by RMB0.1/parcel. According to the six companies, the upward revision of dispatch fee is to support the authority's recently announced opinions regarding the protection of couriers' interest. We believe the government's strong intervention in the express deliver industry will help stop the prolonged cut-throat price war. We start to see some express delivery operators shift the strategy focus from volume to profitability.

- **Our View:** On the back of proven track record of market share gain, strong operational efficiency and cost advantage, ZTO is not only able to mitigate the impact of price war, but also capable to take the opportunity to achieve further share gain and stand out as a long-term winner.

- **Why do we differ vs consensus:** Our earnings forecast in 2021E-23E is 0-5% above consensus estimates. We see upside to our earnings forecast in 2021E, due to potentially higher volume growth in 2H21E.

- **Catalysts:** (1) Stabilization of ASP; (2) Better-than-expected volume growth.

- **Valuation:** ZTO has been trading at a forward P/E range between 30x-45x since early 2020. Our TP of HK$306 is based on 45x 2021E P/E (historical peak level), to reflect the Company's continuous market share gain and the potential to become a long-term winner in the express delivery market.

Link to latest report: ZTO (2057 HK) – Solid 1Q21 volume with resilient ASP

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	25,214	32,382	40,686	47,668
YoY growth (%)	14	28	26	17
Net income (RMB mn)	4,312	4,727	6,249	7,778
EPS (RMB)	5.43	5.66	7.49	9.32
YoY growth (%)	-14.5	4.3	32.2	24.5
Consensus EPS (RMB)	-	5.65	7.10	8.97
EV/EBITDA (x)	21.1	17.3	12.9	10.5
P/E (x)	37.0	33.3	25.2	20.3
P/B (x)	3.4	3.0	2.8	2.5
Yield (%)	0.9	0.9	1.2	1.5
ROE (%)	9.9	9.3	11.4	13.0
Net gearing (%)	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: ZTO's parcel volume growth versus industry



Source: Company data, CMBIS

Li Ning (2331 HK): Continuing to leverage on domestic fashion

Rating: BUY **| TP:** HK$102.84 (2% upside)

Analyst: Walter Woo

- **Investment Thesis:** We are impressed once again by margin expansions in 2H21 and continued to believe Li Ning to benefit the most under domestic fashion mania, even though its growth driver may shift from margins to sales in the next few years. It is a leading sportswear brand in China with RMB 14.6bn sales and around 7,000 stores in FY20. Growth drivers include 1) premiumization and better product mix, 2) ramp up of E-commerce and direct retail, 3) larger sized stores with better productivity.

- **Our View:** Even though there were some drags by covid-19 outbreak on retail sales in Jul-Aug 2021, but we remained highly positive on its outlook in 2H21E and 1H22E, thanks to: 1) remarkable momentum of 30%+ in Jul-Aug 2021, 2) healthy channel inventory level and robust FY22E trade fair sales growth, 3) GP margin expansion, by ASP increase and reduced retail discounts and 4) boost in operational efficiency under the new CEO, etc.

- **Why do we differ vs consensus:** For FY21E/ 22E/ 23E, our net profit forecasts are lower than the street by 1%/ 4%/ 12%, due to our more conservative view, as the base is getter higher and higher, which may result in slower sales growth and greater operating leverage.

- **Catalysts:** 1) robust 2H21E retail sales data point, 2) stronger than expected retail discounts and operating leverage and 3) better than expected marketing events.

- **Valuation:** We derived our 12m TP of HK$102.84 based on 50x FY22E P/E. We believe brand elevation and upgrade on store productivity, can all drive decent growth onwards. The stock is not demanding at all, at 49x FY22E P/E, with 43% adj. NP CAGR during FY20-23E.

Link to latest report: Li Ning (2331 HK) – Shifting gears from margin to sales

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Sales (RMB mn)	14,457	20,466	25,128	28,628
YoY change (%)	4.2	41.6	22.8	13.9
Adj. Net profit (RMB mn)	1,698	3,502	4,288	4,963
Adj. EPS - Fully diluted (RMB)	0.68	1.39	1.71	1.98
YoY change (%)	12.5	106.2	22.4	15.7
Consensus EPS (RMB)	N/A	1.41	1.79	2.25
Adj. P/E (x)	125.6	60.1	49.1	42.4
P/B (x)	24.0	17.6	13.8	11.1
Yield (%)	0.2	0.5	0.6	0.7
ROE (%)	19.5	30.0	28.7	29.6
Net debt/ equity (%)	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: Sales and net profit growth



Source: Company data, CMBIS estimates

Prada (1913 HK): Turnaround confirmed after the strong beat

Rating: BUY **|** **TP:** HK$68.09 (48% upside)

Analyst: Walter Woo

- **Investment Thesis:** The remarkable 1H21 result beat is certainly a confirmation of Prada's long waited turnaround. Thanks to the historical heritage, exclusivity and superior brand equity, luxury brands tend to be the winners in history and short term volatility can be a good entry point. Prada is one of the most prestige luxury brand in the world with EUR 2.4bn sales and 659 stores in FY20. Growth drivers include: 1) better store productivity, 2) ramp up of e-commerce sales and 3) ASP increases by brand elevation.

- **Our View:** Market was worried about potential slowdown in China growth due to recent crackdowns in different industries but we do think Prada's internal growth can offset those negatives. The brand upcycle is still at the early stage and we are positive on 2H21E and FY22E, thanks to: 1) accelerating retail sales growth in Jul 2021, even faster than 12-13% in 2Q21 (vs 2019 level), excellent new product reception in Greater China and US, 3) meaningful wealth effect, 4) effective marketing (fashion shows, sponsorships, crossovers). With strong sales per store growth momentum, we believe its EBIT margin can recover quickly to 15%+ by FY23E.

- **Why do we differ vs consensus:** For FY21E/ 22E/ 23E, our net profit forecasts are 13%/ 5%/ 0% higher than the street, given a faster sales growth, better GP margin and operating leverage.

- **Catalysts:** 1) strong 3Q21E data points, 2) positive peers and industry data points, and 3) positive feedback on its marketing.

- **Valuation:** We derived our 12m TP of HK$68.09 based on 55x FY22E P/E. We believe Prada can continue to outperform industry (unlike FY14 -18), and sentiment can stay positive and support its relatively high valuation. The stock is trading at 39x FY22E.

Link to latest report: Prada (1913 HK) – Turnaround confirmed after the strong beat

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Sales (RMB mn)	2,423	3,218	3,669	4,015
YoY change (%)	(24.9)	32.8	14.0	9.4
Net profit (RMB mn)	(54)	254	347	431
EPS - Fully diluted (RMB)	(0.021)	0.099	0.136	0.168
YoY change (%)	(54)	254	347	431
Consensus EPS (RMB)	N/A	0.090	0.134	0.160
P/E (x)	(249.0)	53.1	38.8	31.3
P/B (x)	4.8	4.4	4.1	3.9
Yield (%)	0.7	1.1	2.1	2.6
ROE (%)	(1.9)	8.6	11.0	12.7
Net debt/ equity (%)	10.9	6.0	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: Sales and net profit growth



Source: Company data, CMBIS estimates

Innovent Biologics (1801 HK): Building world-leading innovation platform

Rating: BUY | **TP:** HK$116.89 (76% upside) Analysts: Jill Wu/ Sam Hu/ Jonathan Zhao

- **Investment Thesis:** Innovent is a leading integrated biopharma company with comprehensive innovative pipelines including mAbs, bsAbs, small molecules and CAR-Ts, covering oncology, autoimmune and metabolic diseases. Besides 5 marketed products (sintilimab, three biosimilars and pemigatinib), Innovent has 6 innovative drugs in pivotal clinical stage, including IBI306 (PCSK9 mAb), IBI310 (CTLA-4 mAb), IBI376 (PI3Kδ inhibitor), IBI326 (BCMA-CART), taletrectinib (ROS1/NTRK inhibitor) and HQP1351 (olverembatinib, 3rd-generation BCR-ABL TKI). In addition, Innovent has established a comprehensive innovative portfolio covering next-generation I/O targets, including KRAS G12C, CD47/SIRPα, TIGIT, LAG3, 4-1BB, etc. It's worth noting that Innovent is an early mover in CD47-SIRPα pathway with three assets under development, including clinical-stage IBI188 (CD47 mAb) and IBI322 (PD-L1/CD47 bsAb), and preclinical stage IBI397 (AL008, SIRPα mAb). As the Company's major source of revenue during recent years, we expect Tyvyt to realize RMB5,974mn and US$1,507mn of peak sales in China and overseas markets, respectively.

- **Our View:** We expect Tyvyt, Byvasda (bevacizumab biosimilar), Sulinno (adalimumab biosimilar) and Halpryza (rituximab biosimilar) will contribute the majority of revenue in the near future. We forecast total revenue to reach RMB3,882mn/ RMB6,098mn/ RMB8,578mn in FY2021E/22E/23E, representing a YoY change of 1%/57%/41%, respectively. We forecast Tyvyt to contribute 74% of Innovent's total revenue in FY21E while the three biosimilars accounting for 26% of the total revenue.

- **Why do we differ vs consensus:** Although our FY21E/22E/23E revenue are -12%/-12%/-6% different from consensus, we are positive on the Company's growth, especially in its fast-growing sales from I/O therapies. With more and more products launch in the near future (commercialization of IBI375, IBI306, IBI310 and IBI376 in China during 2022-23E) and the NDRL inclusion of Tyvyt's large indications in 2021E, we are very optimistic on the Company's profitability.

- **Valuation:** We derive our target price of HK$116.89 based on a 15-year DCF valuation (WACC: 9.30%, terminal growth rate: 4.0%).

Link to latest report: Innovent Biologics (1801 HK) – Building world-leading innovation platform

Financials and Valuations

(YE 31 Dec)	FY21E	FY22E	FY23E
Revenue (RMB mn)	3,882	6,098	8,578
YoY growth (%)	(1)	(57)	(41)
Net profit (RMB mn)	(2,177)	(1,225)	(307)
EPS (RMB)	(1.49)	(0.84)	(0.21)
Consensus EPS (RMB)	(0.93)	(0.26)	0.37
P/S (x)	6.8	7.1	6.8
ROE (%)	(20)	(12)	(3)
Net gearing (%)	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: Revenue trend



Source: Company data, CMBIS estimates

China Pacific Insurance (2601 HK): Expect better-than-peers VNB momentum in 1H21

Rating: BUY **| TP:** HK$35.96 (46% upside)

Analyst: Gigi Chen

- **Investment Thesis:** 1H21 agency new business momentum was better than major peers in spite of a decline in agent headcount, as the insurer continued to focus on agency business and regular pay products. Agency FYP grew 18.5% YoY in 1H21, with agency FYRP up 34%YoY, outperforming the major peers (agency FYP -8% for China Life, +5% for Ping An). Agent productivity increased 41.6% YoY, and average first-year commission income rose 15.1% YoY. The insurer also achieved double-digit growth of health insurance business, outpacing the industry average momentum in 1H21. Looking into 2H21 and 2022, we expect the new initiatives launched at the life arm to improve agent activity and increase top-up sales to existing customers. We also notice the insurer is progressing in technology deployment and innovation which will support growth and improve efficiency, in our view.
- **Long-term growth outlook remains intact:** Given the increasing demand of pension on the back of aging population, we believe that the long-term growth outlook of commercial life insurance remains intact. And we expect insurers with consistent focus on productivity and value to outperform amid the industry-wide agency transformation.
- **Catalysts:** (1) We expect new business momentum to turn around in 2H21 on a low base in 1H20; (2) the new CEO of CPIC Life, Mr. John CAI has conducted his field research over the past months, and we expect to see new strategic initiatives from the management in 2H21.
- **Valuation:** Our PO is based on adjusted appraisal value under the assumptions of (1) 3.0% long-term investment return, (2) 11% risk discount rate, (3) 35% write-down of corporate bonds and non-standard debt investments and (4) 15x NB multiple. The stock is trading at 0.4x/0.3x FY21/22E P/EV or 0.8x/0.7x FY21/22E P/B, with attractive yield at above 7.5%. Reiterate BUY.

Link to latest report: China Pacific Insurance (2601 HK) – Re-energizing agency force

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
GWP (RMB mn)	362,064	379,880	404,464	428,514
YoY growth (%)	4.2	4.9	6.5	5.9
Total income (RMB mn)	418,964	422,765	451,759	480,925
Net profit (RMB mn)	24,584	27,441	30,243	32,957
EPS (RMB)	2.6	2.9	3.2	3.5
YoY Growth (%)	(14.1)	11.6	10.2	9.0
Consensus EPS (RMB)	N/A	2.9	3.2	3.6
P/B (x)	0.8	0.8	0.7	0.7
P/EV (x)	0.4	0.4	0.3	0.3
Yield (%)	6.7	7.4	8.1	8.9
ROE (%)	12.5	12.4	12.7	12.8

Source: Company data, Bloomberg, CMBIS estimates

Fig: Chinese insurers VNB growth forecasts



Source: Company data, Bloomberg, CMBIS estimates

Meituan (3690 HK): Regulation & epidemic impact manageable

Rating: BUY **| TP:** HK$383 (60% upside)

Analysts: Sophie Huang/ Miriam Lu

- **Investment Thesis:** We keep positive on Meituan Dianping's ("MD") secular growth and believe ST headwinds are manageable. Despite temporary pressure from regulation and epidemic, MD is well-positioned to capture LT opportunities from rising online consumption, new initiatives (e.g., community e-commerce), and digital operation. **Our bear case analysis (excl. new biz valuation) indicates HK$180 as fundamental price floor.** Suggest to buy the dips for attractive valuation and potential catalysts from anti-trust fine.

- **Our View:** We expect Meituan's food delivery orders +25% YoY in 3Q21E, with AOV flat QoQ and OPM diluted to 3% by epidemic, natural disasters, and higher subsidies. Given low market expectation, we view such deceleration and margin volatility as acceptable. We anticipate in-store, hotel and travel rev to +31% YoY with OPM at 40% in 3Q21E, due to one-off impact from COVID-19 and flood. As Meituan focuses on LT capability investment for new initiatives, we estimate new biz loss to be RMB10.5bn in 3Q21E (Meituan Select ~RMB7.5bn) with improving UE.

- **Why do we differ vs consensus:** Market concern lies on anti-trust law, social insurance impact, and potential threat from Douyin. We believe near-term concern have been priced in and more prudent monetization outlook was well-guided.

- **Catalysts:** 1) regulation overhangs to lift ; 2) new initiatives to expand TAM (e.g. ride hailing).

- **Valuation:** Maintain BUY with SOTP-based TP of HK$383, implying 8x FY22E P/S. Valuation is attractive, given its 41% FY20- 23E rev CAGR and expanding TAM, in our view.

- **Link to latest report:** [Meituan (3690 HK) – Regulation & epidemic impact manageable]

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	114,795	183,818	253,252	325,206
YoY growth (%)	18	60	38	28
Net income (RMB mn)	3,305	(16,281)	(1,827)	16,092
EPS (RMB)	0.52	(2.64)	(0.29)	2.46
YoY growth (%)	(34)	N/A	N/A	N/A
Consensus EPS (RMB)	NA	(2.53)	0.07	2.97
P/E (x)	397	N/A	N/A	84
P/S (x)	11.4	6.9	5.1	4.2
Yield (%)	0.0	0.0	0.0	0.0
ROE (%)	5.0	(31.1)	(11.2)	11.7
Net gearing (%)	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: MD's revenue growth estimates



Source: Company data, CMBIS estimates

Bilibili (BILI US): Full-year growth intact

Rating: BUY **| TP:** US$110 (28% upside)

Analysts: Sophie Huang/ Miriam Lu

- **Investment Thesis:** We keep bullish on BILI's LT user expansion and monetization enhancement, backed by vibrant community, unique PUGC, strong user stickiness, and enriched offerings. FY21E MAU and rev growth target intact, while segment guidance updated to games/ non-games rev +12~13%/90% YoY (vs. priori +25%/80% YoY). We think softer game guidance is well anticipate by market, given limited new titles in 2H21E. Stock price might see continuous volatility for tightening regulations and weak sector sentiment, but we keep confident on its LT upside.

- **Our View:** Given new games delay, we expect games rev +15% YoY in 3Q21E (vs. prior 24%). In-house game development would be LT strategic priority, while 2H21E eyes on contribution from overseas games and key titles (e.g. *Time Studio*, *Eternal Tree*). Mgmt. expect manageable regulation impact from teenager gaming anti-addiction (1% grossing mix from minors). We expect non-games biz +85% YoY in 3Q21E, and blended GPM -2ppts QoQ to 20% before slightly improving in 4Q21E with LPL rev contribution.

- **Why do we differ vs consensus:** Market concern lies on regulations and rising content cost. BILI's stock price might see continuous volatility for sector de-rating, protection for young gamers, and live streaming regulation headwinds, but we are positive on its long-term topline outlook and user trend.

- **Catalysts:** 1) solid user metrics and topline in 3Q21E; and 2) new games to further boost game rev.

- **Valuation:** We barely changed our full-year estimates but lowered TP to US$110 (8.5x FY22E P/S, vs. prior 11x FY22E P/S) to reflect sector de-rating. Maintain BUY.

- **Link to latest report:** Bilibili (BILI US) – Full-year growth intact

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	11,999	19,119	26,991	35,416
YoY growth (%)	64	59	41	31
Net income (RMB mn)	(2,622)	(4,380)	(5,284)	(5,039)
EPS (RMB)	(7.46)	(13.52)	(15.11)	(14.27)
YoY growth (%)	N/A	N/A	N/A	N/A
Consensus EPS (RMB)	N/A	(11.61)	(9.44)	(3.23)
P/E (x)	N/A	N/A	N/A	N/A
P/S (x)	14.2	8.2	6.3	4.8
Yield (%)	0.0	0.0	0.0	0.0
ROE (%)	(38.56)	(22.6)	N/A	N/A
Net gearing (%)	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: BILI's revenue growth estimates



Source: Company data, CMBIS estimates

CR Land (1109 HK): Rental income to ride on consumption recovery

Rating: BUY **|** **TP:** HK$44.79 (51% upside) Analysts: Jeffrey Zeng

- **Investment Thesis:** In 2021, we favor 1) Names with high % of rent-bearing mall property: We expect a personal spending boom in 2021 on a) high deposit rate (1 - expenditure-to-income ratio) in 2020, b) wealth effect of the stock market, and c) the gradual distribution of COVID-19 vaccines. 2) “Borderline green-zone” names: Under current tight policy and stable market, sales growth depends on an increase in goods value, which in turn depends on an increase in corresponding debt. “Green-zone” (those meeting all three red lines) and “borderline green-zone” (those that can meet all three by YE20) names will have 5-10% edge in debt growth. Such a gap could widen given restricted land cost and rising sales GP margin.

- **Our View:** Investment highlights for CR Land are 1) 30%+ growth in mall rent collection in 2021, 2) CR City Phase IV boosting Shenzhen's sales share and overall GPM. 3) Spin-off of rent collection business to generate value. We see the promotion of CR City Phase IV in Dec 2020 and upcoming results announcement as major catalysts.

- **How do we differ:** Overall, we see the market as over-concerned on 1) further policy tightening and 2) decline in property demand. We think the high saving rate and wealth effect of 2020 would help drive consumption recovery, which would benefit major shopping mall runners in the property space (i.e. CR Land) to accelerate rental income growth.

- **Valuation:** The Company currently trades at 4.8x 2021E P/E vs. historical average of 9x. Moreover, the increase in revenue share of rent collection business could trigger re-rating: see Longfor (960 HK) which currently trades close to 10x 2021E P/E.

Link to latest report: [China Property Sector – Better wait until 4Q to position the sector]

Financials and Valuations

(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E
Revenue (RMB mn)	147,736	179,587	242,568	271,335
YoY growth (%)	21.9	21.2	35.1	11.9
Net income (RMB mn)	28,672	29,810	31,809	34,666
EPS (RMB)	4.12	4.18	4.46	4.86
YoY growth (%)	17.7	1.5	6.7	9.0
Consensus EPS (RMB)	N/A	N/A	4.05	4.63
P/E (x)	5.2	5.1	4.8	4.4
P/B (x)	1.1	1.2	1.1	1.0
Yield (%)	4.0	3.8	4.6	5.1
ROE (%)	16.5	13.7	14.6	14.3
Net gearing (%)	30.3	32.1	31.6	34.4

Source: Company data, Bloomberg, CMBIS estimates

Fig: CR Land’s opening plan



Source: Company data, CMBIS

CG Services (6098 HK): 13-20% earnings boost from Languang acquisition

Rating: BUY | **TP:** HK$91.2 (46% upside)

Analysts: Jeffrey Zeng

- **Investment Thesis:** we are very confident on its >RMB100bn revenue target by 2025E (50% CAGR) as 1) contracted GFA to exceed 1.3bn sq m in 2021E after acquiring Languang; 2) step into commercial property managements which is another blue sea; 3) fast-growing VAS via offering more comprehensive services (e.g. community group shopping, insurance) to increase VAS/sq m to RMB30; and 4) city services to further widen BtoG and BtoB business connection. As a result, we revise up 2021/22E earnings by 10-17% and lift TP to HK$91.2. Reiterate CGS as our Top Pick on growth visibility and VAS. **Catalysts**: 1H21 results beat

- **Our View:** We with high visibility as its parentco could achieve >70mn GFA sales per year. Unlike most players, CGS has turned its M&A focus to community VAS expansion, reflected in City-Media (elevator ads), Hopefluent (real estate agency) and Wenjin International (insurance) acquisitions. Together with CGS' own booming retail business (with the help of its Parentco sourcing), we believe expect managed GFA to grow at a stable 30% CAGR in 2019-2022E the Company would be the key winner in VAS growth.

- **How do we differ:** We value CGS' potential in VAS which the market has not yet recognized. With CGS's strong capital and execution, we think the Company can improve its VAS per sq m from current RMB3/sq m to RMB30/sq m in the future, getting closer to the level of RMB50-56 in US and Japan. We think its Community VAS could contribute as much as RMB5bn net income in the mid-to-long run, and may be worth RMB150bn valuation alone by assigning 30x PE.

- **Valuation:** We derive the target price of HK$91.2/share by using 35x 2022E PE based on the score card. It's currently trading at 21x 2022E PE and looks attractive. We think it will rerate after better-than-expected 1H21 results.

Link to latest report:

China Property Service Sector – Long-term thesis stays unchanged; Pair trade opportunities amid macro and parentco risks

Financials and Valuations

(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E
Revenue (RMB mn)	9,645	15,600	27,265	39,683
YoY growth (%)	106.3	61.7	74.8	45.5
Net income (RMB mn)	1,671	2,686	4,649	6,479
EPS (RMB)	0.63	0.98	1.57	2.20
YoY growth (%)	69.8	55.7	61.3	39.4
Consensus EPS (RMB)	N.A.	N.A.	1.28	1,75
P/E (x)	74.7	48.0	30.0	21.4
P/B (x)	N.A.	23.1	32.9	20.9
Yield (%)	N.A.	0.3	0.7	1.0
ROE (%)	31.1	18.4	25.8	28.3
Net gearing (%)	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: CGS has first-move advantage in VAS acquisitions

Date	Target company	Business	Stake	Consideration (RMB mn)
Apr-20	Wenjin Insurance I	Insurance	100%	84
Apr-20	Hopefluent	Property agency	100%	92
Jul-20	City Media	Elevator ads	100%	1,500

Source: Company data, CMBIS estimates

China Hongqiao (1378 HK): Outstanding 1H21 profitability; aim higher with support from good pricing in 2H21

Rating: BUY | **TP:** HK$15.0 (48% upside) Analyst: Robin Xiao

Investment Thesis: CHQ read 1H21 net profit of RMB8,143mn, up 187.5% YoY, largely in line with our expectation. The Company realized GPM of 30.0%, up 13.8ppt on the back of strong performing aluminum price, significantly higher than our estimates (GPM of 27.7%). Looking ahead in 2H21E, we expect aluminum ASP to be 11.5% higher than 1H21, contributing higher earnings outlook. Trading at 4.0x FY21E PER with attractive dividend yield of 11.7%, we believe CHQ is extremely attractive. We maintain conviction view on CHQ strong fundamentals. TP is maintained at HK$15.0.

- **1H21 profitability beat our expectation.** The Company recognized fair value loss of RMB1,166mn during 1H21, mainly due to non-cash and non-business CB valuation impact. Profit of the period was RMB8,424mn, up 200.4% YoY, in line with CHQ's positive profit alert. Stripping out fair value impact, CHQ's 1H21 core earnings would be RMB9.3bn, significantly beating our expectation.

- **Earnings to boom higher with good aluminum pricing**. 1H21 aluminum sales volume was largely stable, while we estimate realized ASP (VAT incl.) exhibited a significant jump to RMB17.4k/ton. In 2H21E, with reference to recent good performing aluminum price(above RMB20,200/ton), we expect ASP to increase by another 11.5% to RMB19.36k/ton(VAT incl.).Given capacity expansion is largely curb due to China's tightening carbon emission controls, we are now more optimistic on 2022-23 aluminum prices.

- **Conviction BUY at an extremely attractive valuation.** We lifted FY21-23E earnings by 17.4-19.8% to RMB19.0/20.4/21.4bn respectively on higher aluminum ASP outlook. CHQ is only trading at 4.0/3.8x FY21/22E PER, and the Company is paying generous dividend ratio（48% payout）with potential yield to reach 11.7%/12.6% respectively. **We maintain our conviction view on CHQ strong fundamentals. TP is unchanged at HK$15.0.**

Link to latest report: China Hongqiao(1378 HK) – Outstanding 1H21 profitability; aim higher with support from good pricing in 2H21

Financials and Valuations

(YE 31 Mar)	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	86,145	109,768	112,659	114,443
YoY Growth（%）	2.33	27.42	2.63	1.58
Net Income (RMB mn)	10,496	19,099	20,375	21,448
EPS (RMB)	1.22	2.12	2.23	2.35
EPS CHG (%)	72.3	73.8	5.3	5.3
Consensus EPS (RMB)	1.12	1.60	1.77	2.26
PE (x)	7.6	4.4	4.2	4.0
PB (x)	0.80	0.67	0.59	0.53
Yield (%)	5.75	10.7	11.5	12.1
ROE (%)	15.2	22.2	20.6	19.4
Net gearing (%)	39.7	19.9	3.7	-9.9

Source: Company data, Bloomberg, CMBIS estimates

Fig: CHQ's net profit vs. net margin



Source: Company data, CMBIS estimates

BYDE (285 HK): Strong outlook with multiple drivers ahead

Rating: BUY **| TP:** HK$49.5 (41% upside)

Analysts: Alex Ng/ Lily Yang

- **Investment Thesis:** BYDE is the leading vertically integrated handset assembly/component supplier in China. Its major clients include Xiaomi, Apple, Oppo and other handset/PC brands. We believe BYDE will benefit from OEM industry consolidation, Apple/Xiaomi's supplier diversification strategy and strong demand from medical products in 2021-23E.

- **Our View:** We believe share gain in Xiaomi /iPad OEM, smart/automobile products and e-cigarette ramp remain on track in 2H21E despite near-term headwinds on chip shortage. 1) Xiaomi**:** We expect BYDE's EMS share allocation from Xiaomi to increase to 40% in FY21E from 10-20% in FY20E. 2) Apple: We believe BYDE will expand its iPad share allocation to 30-40% in 2021. We expect BYDE to gain share in iPhone/Watch ceramic products and also penetrate into iPad metal casing and front glass. We forecast Apple revenue will reach RMB50bn in FY23E. 3) e-cigarette: 40 automated production line for e-cigarette products have been installed, and total shipment can reach 4mn per day at full utilization in 2022E.

- **Why do we differ vs consensus:** We expect revenue will accelerate to 22%/30% YoY growth in 3Q/4Q21E (vs +8% in 2Q21), driven by Android flagship launches and iPad ramp. We also expect earnings growth to resume at 32% YoY in 4Q21E after 55% YoY decline in 3Q21E.

- **Catalysts:** Near-term catalysts include faster share gain and Xiaomi/Apple product launches, and e-cigarette progress.

- **Valuation:** Our prior SOTP-based TP of HK$49.5.0 implies 16.4x FY21E P/E, which reflect BYDE's business diversification with different growth profiles and visibility.

Link to latest report: BYDE (285 HK) – Outlook intact despite NT headwinds; Maintain BUY

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	73,121	97,307	117,744	147,850
YoY growth (%)	37.9	33.1	21.0	25.6
Net profit(RMB mn)	5,441	3,937	5,643	7,306
EPS (RMB)	2.41	1.75	2.50	3.24
YoY growth (%)	240.6	(27.6)	43.3	29.5
Consensus EPS (RMB)	NA	1.96	2.57	3.15
P/E (x)	12.2	16.9	11.8	9.1
P/B (x)	4.4	3.8	3.2	2.6
Yield (%)	0.8	0.6	0.8	1.1
ROE (%)	24.9	15.5	18.5	19.7
Net gearing (%)	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: BYDE Revenue trend



Source: Company data, CMBIS estimates

Willsemi (603501 CH): A diversified & established global CIS player

Rating: BUY | **TP:** RMB370.75 (55% upside)

Analysts: Lily Yang/ Alex Ng

- **Investment Thesis:** Willsemi is a top 3 manufacturer in global CIS market. We forecast Willsemi's revenue/NP to grow at 32%/43% 2020-23E CAGR, driven by strong demand for CIS from mobile, automotive, VR/AR and other fast-growing end markets. We believe Chinese CIS players will be major beneficiaries of China semi localization and expanding global CIS market (7.2% 21E-26E CAGR).
- **Our View:** We view recent correction as an attractive opportunity for investors to gain exposure to quality Chinese semi fabless names that can ride strategic trends. During recent correction, the stock now trades at attractive valuation of 34.3x FY22E P/E, 1-SD below 2-year historical fwd P/E. We maintain BUY with 12m TP of RMB370.75, as we think Willsemi is an established player with diversified product portfolio.
- **Why do we differ vs consensus:** Although there are mixed views on smartphone camera spec, we believe mobile CIS will continue to deliver solid results on smartphone updates. Meanwhile, we would like to emphasize the greater potentials beyond mobile market, which has stronger demand and higher GPM. We believe earnings contribution from non-mobile CIS will surpass mobile CIS in FY22E thanks to rapid growth in automobile, security, AR/VR and medical.
- **Catalysts:** Near-term catalysts include new VR products to be released by Oculus.
- **Valuation:** Our TP of RMB370.75 by applying 50x FY22E P/E, in-line with 1SD above 2-year historical forward P/E.

Link to latest report:

- Willsemi (603501 CH) – The next chapter beyond mobile CIS is coming
- China CIS market – Beginning of multi-year growth cycle; Initiate BUY

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Revenue (US$ mn)	19,824	29,203	36,723	45,061
YoY growth (%)	45.4%	47.3%	25.7%	22.7%
Gross margin (%)	29.9%	32.5%	33.2%	33.3%
Net profit (US$ mn)	2,706	4,838	6,487	7,904
EPS (US$)	3.21	5.58	7.48	9.11
YoY growth (%)	322.4%	73.7%	34.1%	21.8%
Consensus EPS (US$)	3.21	5.30	6.78	8.58
PE (x)	79.9	46.0	34.3	28.2
PB (x)	19.2	13.4	9.8	7.3
ROE (%)	23.5%	28.5%	27.8%	25.4%
Net gearing (%)	6.7%	Net cash	net cash	net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: Willsemi Revenue trend



Source: Company data, CMBIS estimates

Hikvision (002415 CH): Intelligent camera leader

Rating: BUY **| TP:** RMB80.00 (55% upside)

Analyst: Marley Ngan

- **Investment Thesis:** Hivision is more than a surveillance camera provider as camera applications are expanded by embedding AI/ sensor technology. Hikvision products cover 70 industries and EBG (enterprise) is replacing PBG (public security) as the new growth driver. We expect Hikvision to deliver 22% net profit CAGR in FY20-23E.

- **Our View:** We like Hikvision for its camera technology leadership and continuous margin improvement. Given diversified customer mix, Hikvision can achieve stable growth and face less policy risk. Hikvision Innovative business segments (smart home products/ robotics/ thermal/ x-ray products etc.) is gaining traction, revenue was up +122% YoY to RMB5.6bn in FY1H21 and contributed 16% of total revenue. Gross margin is also improving (+3.1 pct pts to 41.6% in FY1H21), narrowing the gap with core surveillance GPM of 47.2%.

- **Why do we differ vs consensus:** Hikvision has adopted high inventory level strategy since Hisilicon ban in 2019. This helps secure customers and gain market share amid global raw material shortage, especially for SMBG (SME customers) and overseas business.

- **Catalysts:** Accelerating enterprise digitalization, public security projects bidding grow faster than expected.

- **Valuation:** We derive our target price of RMB80.00 on 36x FY22E P/E, 50% above its 3-year mean. Hikvision deserves re-rating as 1) supply chain risk is mitigated after two years of product re-design and 2) strong growth in innovative business proves Hikvision transformation to an intelligent camera solution provider.

Link to latest report: Hikvision (002415 CH) – Innovative business gaining momentum

Financials and Valuations

(YE 31 Dec)	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	63,503	80,603	95,313	109,022
YoY growth (%)	10%	27%	18%	14%
Net profit (RMB mn)	13,386	16,969	20,747	24,187
EPS (RMB)	1.43	1.82	2.22	2.59
YoY growth (%)	8%	27%	22%	17%
Consensus EPS (RMB)	1.43	1.79	2.16	2.55
PE (x)	35.8	28.2	23.1	19.8
PB (x)	8.9	7.5	6.4	5.5
Dividend Yield (%)	0.01	0.01	0.02	0.02
ROE (%)	27%	29%	30%	30%
Net debt to equity	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

Fig: Hikvision revenue and YoY growth



Source: Company data, CMBIS estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIS

OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888   Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Disclosures & Disclaimers

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this document may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This document has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this document. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this document and CMBIS will not assume any responsibility in respect thereof. This document is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.